LeMaitre Vascular (NASDAQ:LMAT) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.22-0.24 for the period, compared to the Thomson Reuters consensus estimate of $0.24. The company issued revenue guidance of $30.1-30.9 million, compared to the consensus revenue estimate of $30.05 million.LeMaitre Vascular also updated its FY 2019 guidance to $0.88-0.90 EPS.
Several analysts recently weighed in on the company. Barrington Research reissued an outperform rating on shares of LeMaitre Vascular in a report on Tuesday, October 15th. First Analysis lowered LeMaitre Vascular from a strong-buy rating to an outperform rating and boosted their price objective for the company from $37.00 to $40.00 in a report on Thursday. BidaskClub raised LeMaitre Vascular from a buy rating to a strong-buy rating in a report on Friday, September 13th. Lake Street Capital upgraded LeMaitre Vascular from a hold rating to a buy rating and set a $40.00 target price for the company in a research note on Thursday. Finally, Zacks Investment Research downgraded LeMaitre Vascular from a strong-buy rating to a hold rating in a research note on Wednesday, September 25th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $38.75.
LMAT stock traded down $1.63 during midday trading on Thursday, reaching $34.37. The company had a trading volume of 314,000 shares, compared to its average volume of 121,075. The stock has a 50 day moving average price of $33.57 and a 200 day moving average price of $30.16. LeMaitre Vascular has a fifty-two week low of $21.79 and a fifty-two week high of $37.35. The firm has a market capitalization of $692.86 million, a PE ratio of 40.92, a P/E/G ratio of 4.06 and a beta of 1.22.
In other news, CEO George W. Lemaitre sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $32.54, for a total transaction of $65,080.00. Following the completion of the transaction, the chief executive officer now directly owns 3,135,730 shares in the company, valued at $102,036,654.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman George W. Lemaitre sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $32.90, for a total value of $329,000.00. Following the transaction, the chairman now owns 3,135,730 shares of the company’s stock, valued at $103,165,517. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 63,617 shares of company stock valued at $2,148,891. Insiders own 19.60% of the company’s stock.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Further Reading: What is the Fibonacci sequence?
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.